Medica Group PLC Dr. Robert Lavis appointed Group Medical Director (8963L)

TIDMMGP

RNS Number : 8963L

Medica Group PLC

18 January 2021

18 January 2021

Medica Group Plc

Dr. Robert Lavis appointed Group Medical Director to succeed Dr. Stephen Davies upon retirement in May 2021

Medica Group Plc (LSE: MGP, "Medica" or the "Company"), the market leader in the provision of teleradiology services in the UK and Ireland, announces today that Dr. Stephen Davies has decided to retire and to step down from his position as Group Medical Director and as an Executive Director on the Board of Medica. Stephen will be succeeded as Group Medical Director by the Company's current Clinical Director, Dr. Robert Lavis. Stephen will work closely with Robert until his planned departure date of 31 May 2021 to ensure an orderly transition.

Dr. Davies joined Medica in 2013 and during his tenure he has transformed the way the service is delivered from a clinical and governance perspective to establish the Company as the UK leader in teleradiology. He was also influential in the Company's listing on the London Stock Exchange in 2017. More recently, Stephen has played a key role in establishing Medica's presence in Ireland, following the acquisition of Global Diagnostics Ireland, and in the deployment of Medica's first augmented intelligence solution.

Dr. Lavis joined the Medica leadership team in September 2020 and has already been influential in driving the clinical aspects of several key strategic projects, including the delivery of the Company's first augmented intelligence solution into everyday reporting practice. He has also driven improvements in clinical protocols associated with trauma and stroke for urgent NightHawk reporting. Prior to joining Medica, Robert worked as a reporting radiologist for the Company for six years. Robert joined Medica from Gloucester Royal Hospital where he is currently a Consultant Radiologist and former Clinical Director. He has extensive experience of clinical practice, starting out his career as a surgeon before entering radiology with a specialist focus on oncology.

Dr. Stephen Davies commented:

"It has been a real pleasure for me personally to have been given the opportunity to lead the clinical governance function at Medica over the past seven years. There have been many highlights to speak of but the transformation of Medica into the leading, clinically-led teleradiology company in the UK and the subsequent successful listing of the Company on the London Stock Exchange are amongst the main achievements. I have personally worked alongside Robert Lavis over the past four months and have no doubt he will continue the drive to improve and evolve the clinical governance and quality of the service we deliver at Medica. It has been a privilege to serve on the Board of Medica and alongside the Executive team led by Stuart. I wish them all well and look forward to watching the Company continue to grow from strength to strength."

Roy Davis, Chairman added:

"On behalf of the Board, I would like to thank Stephen for his dedication and commitment to Medica over the past seven years, as well as his participation as a member of the Board. I look forward to working alongside Robert who shares Stephen's passion for continuous improvement and his desire to drive change. Robert has already played a key role in a number of transformative projects for the Company and I am excited to see him continue to leverage his experience to deliver meaningful change for the benefit of Medica's customers, employees and shareholders. I wish Stephen well in his retirement and know he will be much missed by myself and all of his colleagues at Medica."

Commenting on his appointment, Dr. Robert Lavis said:

"I am honoured to accept the role of Group Medical Director and to be stepping into Stephen's shoes. In my role as a radiologist at Medica and in my short time as Clinical Director, I have seen the impact that Stephen has made to the clinical processes and governance at the Company. I am committed to continuing his excellent work and using my experience and expertise to continue to improve the quality of our service."

For further information, please contact:

 
 Medica Group Plc: 
  Roy Davis, Chairman 
  Stuart Quin, Chief Executive 
  Officer                         [phone] 
 FTI Consulting 
  Victoria Foster Mitchell 
  Robert Winder                   [phone] 
 

About Medica Group PLC

Medica is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of MRI (magnetic resonance imaging), CT (computerised tomography), ultrasound and plain film (x-ray) images, and the market leader for the provision of retinal diagnostic screening in Ireland. The Company currently offers two primary services to hospital radiology departments:

   --      NightHawk, urgent reporting service, and 

-- Elective which includes routine cross-sectional reporting on MRI and CT scans, and routine plain film reporting on x-ray images.

Medica contracts with the largest pool of consultant radiologists in the UK and Ireland, performing remote access teleradiology across its customer base of more than 100 NHS Trusts in the UK, the Irish HSE, private hospital groups and diagnostic imaging companies. This enables the Company to offer a fast, responsive service both during the day and importantly supporting urgent out-of-hours reporting.

Medica has developed a bespoke, secure IT platform that provides market-leading linkage between a hospital's Radiology Information System (RIS) and consultant radiologists who contract with the Company. Direct RIS access ensures that where the wider patient medical history is available, it can be reviewed by the consultant as part of every report. For more information please visit www.medica.co.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABDGDBCSBDGBU

(END) Dow Jones Newswires

January 18, 2021 02:00 ET (07:00 GMT)